Adaptive Biotechnologies (ADPT) Tops Q2 EPS by 6c; Offers FY22 Revenue Guidance

Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $43.7 million versus the consensus estimate of $42.3 million.

GUIDANCE:

Adaptive Biotechnologies sees FY2022 revenue of $185-195 million, versus the consensus of $187.6 million.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform